How to Get Trulicity in Washington

What Is Trulicity and Why Do Washington Patients Choose It?

Trulicity (dulaglutide) is a GLP-1 receptor agonist that Eli Lilly developed for adults with type 2 diabetes. It works by mimicking incretin hormones, stimulating glucose-dependent insulin secretion while suppressing glucagon release. The drug received FDA approval in 2014 and has since become one of the most widely prescribed once-weekly diabetes injectables in the United States.

Washington state has roughly 630,000 adults living with diagnosed diabetes, according to CDC surveillance data. Many of those patients are candidates for GLP-1 therapy, particularly when metformin alone fails to achieve an A1C target below 7%. The American Diabetes Association's Standards of Care recommend adding a GLP-1 receptor agonist as second-line therapy for patients with established atherosclerotic cardiovascular disease or high cardiovascular risk. That recommendation gained strength after the REWIND trial.

The REWIND trial (N=9,901) followed participants with type 2 diabetes for a median of 5.4 years and found that dulaglutide 1.5 mg weekly reduced the composite outcome of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death by 12% compared with placebo (HR 0.88 to 95% CI 0.79 to 0.99). Roughly 31% of participants had no prior cardiovascular event at enrollment, making REWIND the first GLP-1 cardiovascular outcomes trial to include a substantial primary-prevention population [1].

Step-by-Step: Getting a Trulicity Prescription in Washington

The process starts with a clinical evaluation. A licensed prescriber in Washington will assess your medical history, current medications, kidney function, and glycemic control before writing a dulaglutide prescription.

1. Schedule a visit (in-person or telehealth). Washington's telehealth parity law (RCW 48.43.735) requires commercial insurers to cover telehealth services at the same rate as in-person visits. This means you can consult a prescriber from anywhere in the state via video or phone. Telehealth platforms staffed by Washington-licensed providers can evaluate, prescribe, and submit prior authorization paperwork remotely.

2. Complete required labs. Your provider will typically order:

• HbA1c (must confirm type 2 diabetes diagnosis, generally A1C ≥ 6.5%)
• Fasting blood glucose
• Basic metabolic panel (BMP), including serum creatinine and eGFR
• Lipid panel
• Thyroid function (TSH), since GLP-1 receptor agonists carry a boxed warning about medullary thyroid carcinoma risk observed in rodents

Labs can be drawn at any CLIA-certified facility in Washington. Quest Diagnostics and Labcorp both operate multiple draw sites across King, Pierce, Snohomish, Spokane, and Clark counties.

3. Prior authorization (if required). Most commercial plans and Washington Apple Health (Medicaid) require prior authorization before covering Trulicity. The prescriber submits documentation showing the patient has a confirmed type 2 diabetes diagnosis, has tried or has a contraindication to metformin, and meets plan-specific criteria. Turnaround time is typically 48 to 72 hours for commercial plans and up to 5 business days for Medicaid.

4. Fill the prescription. Once approved, the prescription routes to a retail pharmacy, specialty pharmacy, or mail-order service. Patients typically receive their first Trulicity pen within 3 to 7 business days of pharmacy processing.

Who Can Prescribe Trulicity in Washington?

Three prescriber types hold independent prescriptive authority. MDs and DOs have unrestricted prescribing rights. Nurse practitioners (ARNPs) in Washington gained full practice authority in 2020, meaning they can prescribe Trulicity without physician oversight. Physician assistants (PAs) prescribe under a collaborative agreement but do not require a co-signature for GLP-1 medications.

All three provider types can initiate prior authorization. For telehealth consultations, the prescriber must hold an active Washington state license. Providers licensed only in bordering states (Oregon, Idaho) cannot legally write a prescription for a patient physically located in Washington at the time of the visit, per Washington Medical Commission rules.

Telehealth Options for Trulicity in Washington

Telehealth adoption in Washington surged during the COVID-19 public health emergency and has remained high. A 2023 analysis published in the Journal of General Internal Medicine found that telehealth visits for chronic disease management retained clinical outcomes comparable to in-person care, including glycemic control in type 2 diabetes.

Washington patients can access dulaglutide through several telehealth models:

• Direct-to-patient platforms staffed by Washington-licensed endocrinologists or primary care providers who specialize in metabolic health. These platforms handle labs, prescribing, and prior authorization in a single workflow.
• Health system virtual clinics offered by UW Medicine, Virginia Mason Franciscan Health, MultiCare, and Providence, all of which have endocrinology or diabetes care telehealth programs.
• Primary care telemedicine through federally qualified health centers (FQHCs) like Sea Mar Community Health Centers and Community Health Plan of Washington affiliates, which serve patients on Medicaid.

Washington law does not require an initial in-person visit before a telehealth prescription for established medications like Trulicity. A video evaluation is sufficient for the first visit, though some insurers may have their own policies.

Washington Medicaid Coverage and Prior Authorization

Washington Apple Health (the state Medicaid program) covers Trulicity for type 2 diabetes with prior authorization through the Health Care Authority's (HCA) preferred drug list. The HCA formulary classifies GLP-1 receptor agonists as a managed therapeutic class.

To secure approval, the prescriber must document:

• A confirmed type 2 diabetes diagnosis (ICD-10 E11.x)
• Current or prior metformin therapy of at least 90 days, OR a documented contraindication (eGFR <30 mL/min, lactic acidosis history, GI intolerance requiring discontinuation)
• Most recent A1C value (generally ≥ 7.0% despite current therapy)
• Rationale for selecting dulaglutide over preferred alternatives if another GLP-1 is listed as preferred

Denials can be appealed. Washington's fair hearing process gives Medicaid beneficiaries the right to request an administrative hearing within 90 days of a denial, per WAC 182-526-0005. The average appeal resolution timeline in Washington is 30 to 45 days.

Commercial Insurance and Cost Considerations

For commercially insured patients in Washington, Trulicity's list price is approximately $1,067 for a 4-pen monthly supply (as of early 2026). Actual out-of-pocket cost depends on the plan's formulary tier and benefit design.

The Endocrine Society's clinical practice guideline on type 2 diabetes pharmacotherapy notes that cost remains a significant barrier to GLP-1 receptor agonist adherence, with discontinuation rates reaching 40 to 50% within the first year across real-world studies [2]. Washington patients can reduce costs through:

• Manufacturer savings cards. Eli Lilly offers copay assistance for commercially insured patients, potentially reducing costs to as low as $25 per month for eligible individuals.
• Therapeutic substitution. If a plan excludes Trulicity, the prescriber may request an exception or switch to a covered GLP-1 (semaglutide, liraglutide, or exenatide extended-release).
• Patient assistance programs. Lilly Cares provides free medication to qualifying uninsured patients with household incomes at or below 400% of the federal poverty level.

503A Compounding Pharmacies in Washington

Washington licenses 503A compounding pharmacies under the Washington State Pharmacy Quality Assurance Commission. These pharmacies can prepare patient-specific compounded prescriptions, including GLP-1 receptor agonist formulations, when a licensed prescriber writes an individual prescription.

A few points matter. 503A pharmacies compound based on an individual prescription for a specific patient. They are not permitted to produce large batches for general distribution (that falls under 503B outsourcing facilities regulated by the FDA). Washington-licensed 503A pharmacies can ship compounded medications within the state, and some hold non-resident pharmacy licenses in neighboring states.

The FDA's guidance on compounding under section 503A requires that the compounded drug differ in some meaningful way from the commercially available product (different strength, dosage form, or the addition of a flavor or dye for a patient with a specific need). A prescriber must identify a clinical reason why the commercial product is not suitable.

Dosing and What to Expect After Your First Prescription

Dulaglutide dosing follows a straightforward titration. The starting dose is 0.75 mg injected subcutaneously once weekly. After at least 4 weeks, the dose increases to 1.5 mg weekly if additional glycemic control is needed. The FDA label permits further titration to 3.0 mg and then 4.5 mg at 4-week intervals [3].

The most common side effects are gastrointestinal. In the AWARD-1 trial (N=978), nausea occurred in 39% of patients on dulaglutide 1.5 mg versus 21% on placebo, but typically resolved within 2 weeks [4]. Diarrhea affected 12% of dulaglutide-treated patients.

Patients should inject Trulicity on the same day each week. The pen delivers a fixed dose and does not require manual needle attachment. Injection sites include the abdomen, thigh, or upper arm. Rotate sites weekly to reduce lipodystrophy risk.

Store unused pens in the refrigerator at 36°F to 46°F (2°C to 8°C). A pen can remain at room temperature (up to 86°F / 30°C) for up to 14 days. Do not freeze.

Transferring a Trulicity Prescription to Washington

If you are relocating to Washington from another state, your existing Trulicity prescription can transfer to a Washington pharmacy. The receiving pharmacy contacts your previous pharmacy to verify the prescription details. Washington Board of Pharmacy rules allow pharmacists to accept transferred prescriptions for non-controlled substances without restrictions.

A faster route: ask your new Washington-based provider to write a new prescription. This is often simpler than navigating a transfer, especially if you also need a new prior authorization under a different insurance plan. Bring your most recent lab results and medication list to the first visit to avoid redundant lab draws.

Timeline: From First Visit to First Injection

Speed varies based on insurance. Here is a realistic breakdown:

• Day 1: Telehealth or in-person evaluation; labs ordered
• Days 2 to 4: Lab results returned (most reference labs in Washington report within 24 to 48 hours)
• Days 3 to 5: Prescriber submits prior authorization
• Days 5 to 8: PA decision received (commercial plans average 2 to 3 business days; Medicaid up to 5)
• Days 7 to 14: Pharmacy dispenses and ships or patient picks up

Cash-pay patients who skip prior authorization can often receive their medication within 3 to 5 days if stock is available at a local pharmacy.

Monitoring and Follow-Up in Washington

After starting Trulicity, expect follow-up labs at 3 months. Your provider will recheck A1C, fasting glucose, and renal function. The ADA Standards of Care recommend reassessing glycemic targets every 3 to 6 months and adjusting therapy if A1C remains above goal [5].

Washington telehealth providers can conduct these follow-ups remotely. Lab orders can be sent electronically to any draw site in the state, and results review happens over a video or phone visit. This model works particularly well for patients in rural eastern Washington counties (Ferry, Pend Oreille, Stevens) where endocrinology access is limited to Spokane-based specialists.

Long-term, the REWIND data support continued use: the cardiovascular benefit of dulaglutide 1.5 mg was sustained across the full 5.4-year median follow-up, with a number needed to treat of 60 to prevent one major adverse cardiovascular event over that period [1].